| Literature DB >> 34908855 |
Chang Zhou1, Rui Kang2, Shu Liang1, Teng Fei2, Yiping Li1, Ling Su1, Ling Li1, Li Ye1, Yan Zhang1, Dan Yuan1.
Abstract
BACKGROUND: Sichuan Province, in the interior of Southwest China, is the most severe HIV-affected area in China. Few data are currently available for people living with HIV/AIDS (PLWH) with virological failure of antiretroviral therapy (ART). Estimating the HIV-1 drug-resistant spread influencing factors and transmission patterns of the HIV-1 epidemic of PLWH with ART virological failure are critical in Sichuan.Entities:
Keywords: HIV-1; antiretroviral resistance; spatial analyses; transmitted drug resistance
Year: 2021 PMID: 34908855 PMCID: PMC8666109 DOI: 10.2147/IDR.S334598
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Figure 1The distribution of people living with HIV/AIDS recruited in this study.
Figure 2Resistance-drug transmission sketch map.
Urban Distribution of the Individuals Clustering of DR
| City | Number of Infections | Clusters | Clustering Rate % | Clusters of DR | Clustering Rate of DR (%) |
|---|---|---|---|---|---|
| Chengdu | 524 | 170 | 32.44% | 37 | 7.06% |
| Deyang | 240 | 166 | 69.17% | 55 | 22.92% |
| Leshan | 170 | 76 | 44.71% | 26 | 15.29% |
| Suining | 70 | 28 | 40.00% | 7 | 10.00% |
| Ziyang | 151 | 32 | 21.19% | 14 | 9.27% |
| Mianyang | 250 | 86 | 34.40% | 39 | 15.60% |
| Yaan | 125 | 41 | 32.80% | 16 | 12.80% |
| Meishan | 139 | 48 | 34.53% | 18 | 12.95% |
| Yibin | 595 | 330 | 55.46% | 113 | 18.99% |
| Zigong | 90 | 27 | 30.00% | 8 | 8.89% |
| Neijiang | 392 | 243 | 61.99% | 97 | 24.74% |
| Luzhou | 471 | 223 | 47.35% | 94 | 19.96% |
| Bazhong | 54 | 17 | 31.48% | 8 | 14.81% |
| Nanchong | 153 | 69 | 45.10% | 38 | 24.84% |
| Dazhou | 239 | 78 | 32.64% | 17 | 7.11% |
| Guangyuan | 53 | 23 | 43.40% | 4 | 7.55% |
| Guangan | 183 | 75 | 40.98% | 23 | 12.57% |
| Panzhihua | 144 | 60 | 41.67% | 15 | 10.42% |
| Liangshan | 1724 | 360 | 20.88% | 130 | 7.54% |
| Aba | 12 | 4 | 33.33% | 1 | 8.33% |
| Ganzi | 11 | 3 | 27.27% | 1 | 9.09% |
| Total | 5790 | 2159 | 37.29% | 761 | 13.14% |
Risk Factors of Drug Resistant Nodes with Drug Resistance-Associated Transmission Links ≥2
| Variables | Total | % | ≥Link2 | % | OR | AOR |
|---|---|---|---|---|---|---|
| Male | 1771 | 72.79 | 278 | 15.70 | 1 | |
| Female | 662 | 27.21 | 95 | 14.35 | 0.90 (0.70~1.16) | |
| ≤14 | 90 | 3.70 | 3 | 3.33 | 1 | 1 |
| 15–49 | 1464 | 60.17 | 156 | 10.66 | 3.46 (1.08~11.06)* | 2.07 (0.32~13.45) |
| ≥50 | 879 | 36.13 | 214 | 24.35 | 9.33 (2.92~29.81)*** | 4.27 (0.64~28.34) |
| Farmers | 1559 | 64.08 | 261 | 16.74 | 1 | 1 |
| Workers | 63 | 2.59 | 13 | 20.63 | 1.29 (0.69~2.41) | 1.68 (0.87~3.23) |
| Employed | 656 | 26.96 | 75 | 11.43 | 0.64 (0.49~0.85)** | 0.70 (0.51~0.97)* |
| Students/Children | 108 | 4.44 | 7 | 6.48 | 0.35 (0.16~0.75)** | 2.37 (0.66~8.51) |
| Retired | 47 | 1.93 | 17 | 36.17 | 2.82 (1.53~5.19)** | 1.79 (0.93~3.44) |
| Married or living With spouse | 1298 | 53.35 | 193 | 14.87 | 1 | 1 |
| Single | 562 | 23.10 | 64 | 11.39 | 0.74 (0.54~1.00)* | 1.09 (0.75~1.58) |
| Divorced/widowed | 573 | 23.55 | 116 | 20.24 | 1.45 (1.13~1.88)** | 1.18 (0.93~1.55) |
| Han | 1773 | 72.87 | 307 | 17.32 | 1 | 1 |
| Yi | 639 | 26.26 | 63 | 9.86 | 0.52 (0.39~0.70)*** | 0.70 (0.42~1.16) |
| Others | 21 | 0.86 | 3 | 14.29 | 0.80 (0.23~2.72) | 0.93 (0.26~3.37) |
| Illiteracy | 566 | 23.26 | 74 | 13.07 | 1 | 1 |
| Primary school | 939 | 38.59 | 184 | 19.60 | 1.62 (1.21~2.17)** | 1.06 (0.75~1.49) |
| Middle school | 619 | 25.44 | 77 | 12.44 | 0.95 (0.67~1.33) | 0.76 (0.50~1.15) |
| High school or technical secondary school | 219 | 9.00 | 26 | 11.87 | 0.90 (0.56~1.44) | 0.83 (0.46~1.49) |
| Junior college or above | 90 | 3.70 | 12 | 13.33 | 1.02 (0.53~2.00) | 1.09 (0.49~2.42) |
| Hetero | 1752 | 72.01 | 296 | 16.89 | 1 | 1 |
| MSM | 195 | 8.01 | 27 | 13.85 | 0.79 (0.52~1.21) | 1.38 (0.82~2.31) |
| IDUs | 323 | 13.28 | 44 | 13.62 | 0.78 (0.55~1.09) | 1.70 (1.05~2.76)* |
| Sexual and IDUs | 56 | 2.30 | 2 | 3.57 | 0.18 (0.44~0.75)* | 0.39 (0.09~1.70) |
| MCT | 107 | 4.40 | 4 | 3.74 | 0.19 (0.07~0.52)** | 0.28 (0.43~1.80) |
| ≤200 | 885 | 36.37 | 143 | 16.16 | 1 | 1 |
| 200~500 | 1402 | 57.62 | 216 | 15.41 | 0.95 (0.75~1.19) | 1.07 (0.83~1.39) |
| >500 | 146 | 6.00 | 14 | 9.59 | 0.55 (0.31~0.98)* | 0.71 (0.38~1.34) |
| HIV | 811 | 33.33 | 148 | 18.25 | 1 | 1 |
| AIDS | 1622 | 66.67 | 225 | 13.87 | 0.72 (0.58~0.91)** | 0.69 (0.53~0.89)** |
| Never | 2237 | 91.94 | 331 | 14.80 | 1 | 1 |
| Ever | 196 | 8.06 | 42 | 21.43 | 1.57 (1.10~2.25)* | 1.69 (1.15~2.48)** |
| ≤12 | 378 | 15.54 | 73 | 19.31 | 1 | 1 |
| 12~36 | 956 | 39.29 | 173 | 18.10 | 0.92 (0.68~1.25) | 0.88 (0.64~1.22) |
| >36 | 1099 | 45.17 | 127 | 11.56 | 0.55 (0.40~0.75)*** | 0.66 (0.47~0.92)* |
| First-line treatment | 2390 | 98.23 | 370 | 15.48 | 1 | 1 |
| Second-line treatment | 43 | 1.77 | 3 | 6.98 | 0.41 (0.13~1.33) | 0.72 (0.21~2.42) |
| CRF07_BC | 1320 | 54.25 | 172 | 13.03 | 1 | 1 |
| CRF01_AE | 688 | 28.28 | 102 | 14.83 | 1.16 (0.89~1.51) | 1.01 (0.75~1.37) |
| CRF08_BC | 256 | 10.52 | 53 | 20.70 | 1.74 (1.24~2.45)** | 1.29 (0.88~1.87) |
| CRF85_BC | 107 | 4.40 | 46 | 42.99 | 5.03 (3.32~7.62)*** | 2.86 (1.81~4.51)*** |
| B | 62 | 2.55 | 0 | 0.00 |
Notes:*P < 0.05, **P < 0.01, ***P < 0.001.
Abbreviations: CI, confidence interval; Hetero, heterosexual transmission; MSM, men who have sex with men; IDUs, injection drug users; MCT, mother to child transmission.
Figure 4The geographic dimension of HIV-1 Drug-resistance transmission. (A) HIV-1 transmission in Sichuan. (B) HIV-1 Drug Resistance transmission with virological failure of ART in Sichuan. Circles with different size represents the number of individuals with drug resistance-associated transmission links within the region; the lines with different colors represent the number of individuals with drug resistance-associated transmission links between regions.
Links of HIV DRMs with Subtype in Transmission Network
| DRMs | B (n=15) | 07BC (n=1975) | 01AE (n=1450) | 08BC (n=505) | 85BC (n=896) | χ2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 4 | 26.67% | 306 | 15.49% | 137 | 9.45% | 92 | 18.22% | 108 | 12.05% | 40.83 | <0.001 |
| PI | 0 | 0.00% | 11 | 0.56% | 1 | 0.07% | 1 | 0.20% | 0 | 0.00% | 10.84 | 0.028 |
| M46I/L | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 1 | 0.20% | 0 | 0.00% | 4.46 | 0.347 |
| I54V | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| V82A | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| K43T | 0 | 0.00% | 2 | 0.10% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 1.38 | 0.847 |
| L10F/I | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| L24I | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| T74P | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| Q58E | 0 | 0.00% | 10 | 0.51% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 14.54 | 0.006 |
| NRTI | 3 | 20.00% | 169 | 8.56% | 56 | 3.86% | 63 | 12.48% | 9 | 1.00% | 113.24 | <0.001 |
| A62V | 0 | 0.00% | 1 | 0.05% | 2 | 0.14% | 0 | 0.00% | 0 | 0.00% | 2.28 | 0.686 |
| D67N | 0 | 0.00% | 22 | 1.11% | 15 | 1.03% | 36 | 7.13% | 1 | 0.11% | 122.01 | <0.001 |
| E44D/A | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| K65R/E | 1 | 6.67% | 12 | 0.61% | 20 | 1.38% | 11 | 2.18% | 2 | 0.22% | 23.63 | <0.001 |
| K70R/E/T/S/Q/H/G | 1 | 6.67% | 17 | 0.86% | 20 | 1.38% | 51 | 10.10% | 2 | 0.22% | 213.25 | <0.001 |
| K219E/Q/R | 1 | 6.67% | 20 | 1.01% | 18 | 1.24% | 45 | 8.91% | 0 | 0.00% | 178.59 | <0.001 |
| L74I/V/F | 1 | 6.67% | 4 | 0.20% | 4 | 0.28% | 1 | 0.20% | 0 | 0.00% | 32.56 | <0.001 |
| L210W | 0 | 0.00% | 10 | 0.51% | 3 | 0.21% | 0 | 0.00% | 0 | 0.00% | 8.19 | 0.085 |
| M41L | 0 | 0.00% | 13 | 0.66% | 3 | 0.21% | 0 | 0.00% | 1 | 0.11% | 9.49 | 0.05 |
| M184V/I | 2 | 13.33% | 81 | 4.10% | 35 | 2.41% | 52 | 10.30% | 6 | 0.67% | 97.89 | <0.001 |
| T215F/Y/S | 0 | 0.00% | 6 | 0.30% | 7 | 0.48% | 45 | 8.91% | 1 | 0.11% | 277.76 | <0.001 |
| V75I/M | 0 | 0.00% | 5 | 0.25% | 3 | 0.21% | 0 | 0.00% | 0 | 0.00% | 3.42 | 0.49 |
| Y115F/Y | 0 | 0.00% | 3 | 0.15% | 3 | 0.21% | 0 | 0.00% | 1 | 0.11% | 1.22 | 0.875 |
| NNRTI | 4 | 26.67% | 273 | 13.82% | 134 | 9.24% | 89 | 17.62% | 103 | 11.50% | 33.03 | <0.001 |
| A98G/A | 0 | 0.00% | 3 | 0.15% | 4 | 0.28% | 0 | 0.00% | 1 | 0.11% | 2.11 | 0.715 |
| E138A/Q/G/K | 0 | 0.00% | 7 | 0.35% | 2 | 0.14% | 1 | 0.20% | 0 | 0.00% | 4.31 | 0.365 |
| F227L/C | 0 | 0.00% | 5 | 0.25% | 3 | 0.21% | 0 | 0.00% | 2 | 0.22% | 1.30 | 0.862 |
| G190A/S/C/Q | 1 | 6.67% | 14 | 0.71% | 20 | 1.38% | 10 | 1.98% | 2 | 0.22% | 19.55 | 0.001 |
| H221Y | 0 | 0.00% | 8 | 0.41% | 2 | 0.14% | 7 | 1.39% | 3 | 0.33% | 14.49 | 0.006 |
| K101E/Q/H/P/A | 1 | 6.67% | 13 | 0.66% | 10 | 0.69% | 2 | 0.40% | 1 | 0.11% | 14.36 | 0.006 |
| K103N/S/E/Q | 1 | 6.67% | 164 | 8.30% | 46 | 3.17% | 34 | 6.73% | 50 | 5.58% | 39.26 | <0.001 |
| K238T/N | 0 | 0.00% | 0 | 0.00% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 2.34 | 0.674 |
| L100I/S/V/F | 0 | 0.00% | 1 | 0.05% | 1 | 0.07% | 0 | 0.00% | 0 | 0.00% | 0.90 | 0.925 |
| M230L/I | 0 | 0.00% | 2 | 0.10% | 0 | 0.00% | 1 | 0.20% | 0 | 0.00% | 3.47 | 0.483 |
| P225H | 1 | 6.67% | 0 | 0.00% | 2 | 0.14% | 2 | 0.40% | 1 | 0.11% | 57.38 | <0.001 |
| V106M/V/A | 2 | 13.33% | 24 | 1.22% | 18 | 1.24% | 2 | 0.40% | 10 | 1.12% | 22.17 | <0.001 |
| V108I | 0 | 0.00% | 6 | 0.30% | 14 | 0.97% | 56 | 11.09% | 0 | 0.00% | 334.58 | <0.001 |
| V179D/E | 0 | 0.00% | 44 | 2.23% | 22 | 1.25% | 9 | 1.78% | 31 | 3.46% | 10.55 | 0.032 |
| Y181C | 1 | 6.67% | 45 | 2.28% | 11 | 0.76% | 52 | 10.30% | 5 | 0.56% | 168.44 | <0.001 |
| Y188L/C | 0 | 0.00% | 4 | 0.20% | 6 | 0.41% | 0 | 0.00% | 1 | 0.11% | 3.99 | 0.407 |
Notes: PI: PI resistance in both connected sequences; NRTI: NRTI resistance in both connected sequences; NNRTI: NNRTI resistance in both connected sequences; each drug resistance site stands for the drug resistance site in both connected sequences; n: the total number of sides after the subtype sequence constructs the molecular network.
Abbreviations: NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.